Moderna's production lab and space has been increased from approximately 300,000 sq ft to approximately 650,000 sq ft. In addition, the firm acquired a 240,000-sq-ft building on the same campus in order to expand its commercial and clinical activities.
The expansion will enable a 50% increase in production of Moderna's COVID-19 vaccine at the manufacturing site beginning in late 2021 and early 2022, according to the company. Late last month, Moderna also announced investments in its owned and partnered manufacturing facilities that it expects would increase 2022 global capacity to up to 3 billion doses of its COVID-19 vaccine. It also raised its 2021 manufacturing supply forecast to be between 800 million and 1 billion doses.
Copyright © 2021 scienceboard.net